高级检索
当前位置: 首页 > 详情页

Tetrahydroxy Stilbene Glycoside Reduces Abeta Deposition by Modulating Microglia Activation and via TREM2/PI3K/AKT Pathway in APP/PS1 Mice

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Tongren Hosp, Dept Anesthesiol, Beijing, Peoples R China [2]Capital Med Univ, Beijing Shijitan Hosp, Biomed Innovat Ctr, Beijing, Peoples R China [3]Capital Med Univ, Beijing Shijitan Hosp, Beijing Key Lab Therapeut Canc Vaccines, Beijing, Peoples R China [4]China Acad Chinese Med Sci, Inst Basic Theory Chinese Med, Beijing, Peoples R China [5]Capital Med Univ, Beijing Shijitan Hosp, Dept Anesthesiol, Beijing, Peoples R China
出处:
ISSN:

关键词: Alzheimer's disease microglia tetrahydroxy stilbene glycoside traditional Chinese medicine TREM2/PI3K/AKT pathway

摘要:
Tetrahydroxy stilbene glycoside (TSG), which is the primary active substance of Chinese herbal medicine called Polygonum multiflorum, has been acknowledged to alleviate Alzheimer's disease (AD)-induced learning disorder in the transgene mice. Because the microglia activation is really important during the AD progression, herein, we determined the effects of TSG on AD neuropathology, microglia polarization and its underlying mechanism. We used APP/PS1 mice along with immunohistochemistry and immunofluorescence techniques to evaluate the function of TSG as 60, 120 and 180 mg/kg on A beta deposition, neuronal loss and microglia polarization induced by AD. Additionally, we assessed the effects of TSG on TREM2 signalling using both molecular docking and Western blot analysis. TSG was found to promote neuronal survival and decrease A beta deposition in APP/PS1 mice. Moreover, TSG reduced microglia M1 polarization and modulated the TREM2/PI3K/AKT signalling pathways. TSG could reduce neuronal impairment by mediating the microglia polarization by TREM2/PI3K/AKT signalling pathway in APP/PS1 mice and is a latent pharmacological research direction for the therapy in the patients with AD.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 4 区 医学
小类 | 3 区 毒理学 4 区 药学
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 毒理学 4 区 药学
JCR分区:
出版当年[2023]版:
Q2 PHARMACOLOGY & PHARMACY Q3 TOXICOLOGY
最新[2024]版:
Q2 PHARMACOLOGY & PHARMACY Q2 TOXICOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Tongren Hosp, Dept Anesthesiol, Beijing, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [2]Capital Med Univ, Beijing Shijitan Hosp, Biomed Innovat Ctr, Beijing, Peoples R China [3]Capital Med Univ, Beijing Shijitan Hosp, Beijing Key Lab Therapeut Canc Vaccines, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:28508 今日访问量:0 总访问量:1584 更新日期:2025-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)